Health Care & Life Sciences » Biotechnology | ReNeuron Group PLC

ReNeuron Group PLC | Income Statement

Fiscal year is April-March. All values GBP Thousands.
2014
2015
2016
2017
2018
Sales/Revenue
22.00
30.00
29.00
46.00
43.00
SG&A Expense
8,427.00
10,577.00
14,190.00
19,027.00
21,041.00
EBIT
8,517.00
10,772.00
14,258.00
18,296.00
21,230.00
Unusual Expense
114.00
141.00
-
1,591.00
-
Non Operating Income/Expense
750.00
519.00
1,067.00
1,202.00
57.00
Pretax Income
7,820.00
10,303.00
12,846.00
18,165.00
20,967.00
Income Tax
754.00
1,397.00
1,492.00
2,592.00
3,352.00
Consolidated Net Income
7,066.00
8,906.00
11,354.00
15,573.00
17,615.00
Net Income
7,066.00
8,906.00
11,354.00
15,573.00
17,615.00
Net Income After Extraordinaries
7,066.00
8,906.00
11,354.00
15,573.00
17,615.00
Net Income Available to Common
7,066.00
8,906.00
11,354.00
15,573.00
17,615.00
EPS (Basic)
0.50
0.50
0.40
0.50
0.56
Basic Shares Outstanding
14,249.80
17,888.30
26,093.20
31,646.20
31,646.20
EPS (Diluted)
0.50
0.50
0.44
0.49
0.56
Diluted Shares Outstanding
14,249.80
17,888.30
26,093.20
31,646.20
31,646.20
EBITDA
8,405.00
10,647.00
14,166.00
18,127.00
20,998.00
Other Operating Expense
-
100.00
5.00
854.00
-
Non-Operating Interest Income
61.00
91.00
345.00
520.00
320.00

About ReNeuron Group

View Profile
Address
Pencoed Business Park
Pencoed BJ CF35 5HY
United Kingdom
Employees -
Website http://reneuron.com
Updated 07/08/2019
ReNeuron Group Plc engages in the development of novel cell based therapies that target significant areas of unmet medical need. It develops its core stem cell assets such as CTX neural cell line and human retinal progenitor cells. The company was founded by John David Sinden in 1997 and is headquartered in Pencoed, the United Kingdom.